Member Info for chester18

Nice buy Quoth

As we continue to put these shares away it’s going to make it very difficult to establish big holding in Scancell without the price rising even further.

I said last week that there is a good chance of seeing 13.8p very shortly.

👍👍

At the same time Crusty a sale of that size would normally put the SP backwards but it’s been soaked up by all the buying. Which is a big positive.

I hope that is the last of these surprise hits.

That’s a very odd trade.

A sell of such magnitude would have been 12p or below. A worked Buy over the last 3/4 weeks would have been printed before now as there has not enough sell volume under that price for a day or so.

So very odd size at just under 13p ??

Thank you JWHG

Good research and confirms that at least one GlyMab Target is moving forward.

The move into a phase 1 gives us all new hope that our GlyMab program is as Phil proclaimed “a goldmine”.

👊👊

That is what is at stake for West Coast Silver.

Huge ‘native silver’ grams per tonne means it’s very cost effective but it needs the volume.

If this hypothesis that the silver is distributed in multiple pods and spread out away from the existing mine footprint, then the economics become Bonanza grade. Never mind the 33,000 gms/tonne hits in the recent diamond drilling.

If these AirCore results are good it has to lift UFO.

GLA

Like UnbelievaMab or WowzerMab …,,

They sound like fairly good Mabs 😂😂

Botski2

Bit of fun on a cold rainy day, but yep.

These are the little bits of info we like to unearth and muse about while we bide our time.

We’ve now got GenMabs year end report to dissect on Wednesday night …… gives me a warm glow. 🤣🤣🤣

Ok I didn’t account for the cheeseburgers being off 🍔

But apart from being to busy dealing with MHRA and EMA, chatting to a few blokes about finance and the nutritional value of burgers at AACR , what could be the reason for not going ? 🤓

Being serious, it was an important showcase for the data last year……

“Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announce translational data from the SCOPE trial demonstrating SCIB1 combined with nivolumab and ipilimumab will be presented during a poster session at the AACR IO conference, taking place in Los Angeles, California on 23-26 February 2025”.

So something has changed if we don’t go and that something has to be ‘engagement’.

Last year we were still trying to get attention and now maybe we’re not.

I think it strongly suggests that we are definitely in dialogue and don’t need to tout our wares elsewhere …… 👍

Crusty

‘Or radio silence’ 🤔

AACR IMMUNO-ONCOLOGY CONFERENCE .

February 18-21, 2026

As I posted a few days ago, Scancell presented a poster at this event last year.

If we are attending or presenting surely we would know by now.

And, if we are not showing up to event what does that tell us ?

Anyone any ideas ?

Excellent.

Sometimes LSE doesn’t load all the trading information correctly. Well worth checking the page if you’re interested in what trades are going through. It also has the 15 minute delay like LSE.

For your information it doesn’t show any trades processed on Aquis ( that’s : Scancell Holdings PLC ) but currently it is very rarely used.

Hi vascular

Try this link to the London Stock exchange.

In the search box input SCLP or Scancell and when that page loads scroll down to today’s trades, in fact there will be all trades going back a few days.

Let me know how you get on.

https://www.londonstockexchange.com/news?tab=news-explorer&period=daily&headlinestypes=1,2

Just announced on ASX.

Does this point to the AirCore results being of high quality and some validation of the multiple Pods theory?

AACR IMMUNO-ONCOLOGY CONFERENCE (AACR IO)

Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy

February 18-21, 2026

JW Marriott Los Angeles L.A. Live

Los Angeles, California

We presented a poster at last year’s conference. No word so far, but is Scancell there this year ??

Absolutely Wildforce

I’m the same, shares tucked up in an ISA.

It just looks like the game has changed because up to the end of last year every single rise was destroyed by a fund having to sell out.

Right now I think we have at least one and hopefully two serious buyers. They want our shares either at a target price or a target percentage of Scancell.

The game is a foot, as they say 🤣🤣

Wildforce

It will be interesting to see how the share price fairs on Monday. If most shares are now in the hands of investors looking for mid-twenties before they’ll sell any quantity and it does feel that’s the case. Set that against a buyer with a target percentage in mind and is hopefully committed to the task up to, say 30p. We’ll see the sp rise rapidly.

Best way to test, is anyone reading this post to definitely not sell a share until we hit 20p +.

If there are very few or no sells it will put pressure on the MM’s to raise the price.

It would be nice to watch if true 👊👊

C11

Tuesday would do very nicely 👍

Either or both together, I’m not to greedy.

Ray you are correct.

“ We compared regulatory market authorisation dates at the FDA and EMA for new oncology therapies from ……..”

Hi C11

What would have been helpful in that report was in the 80 approved by both where the FDA approved first, what was the average delay in receiving approval from the EMA.

Basically, if the FDA give a green light does that speed up the process for the EMA ?

From what Phil said, both the MHRA and the EMA do accept that FDA approval is a major step forward to ensuring their approval.

What we don’t know is when did Scancell put in the paperwork for MHRA or EMA. I’m hoping it was shortly after they got the FDA documents emailed at the end of December.